Pharmacologic Management of Type 2 Diabetes Mellitus: Available Therapies

This publication has 63 references indexed in Scilit:

• Peroxisome Proliferator-Activated Receptor Targets for the Treatment of Metabolic Diseases
  Mediators of Inflammation, 2013
• Metformin: an old but still the best treatment for type 2 diabetes
  Diabetology & Metabolic Syndrome, 2013
• Effect of Bromocriptine‐QR (a Quick‐Release Formulation of Bromocriptine Mesylate) on Major Adverse Cardiovascular Events in Type 2 Diabetes Subjects
  Journal of the American Heart Association, 2012
• Quantifying the Effect of Metformin Treatment and Dose on Glycemic Control
  Diabetes Care, 2012
• The Effect of Oral Antidiabetic Agents on A1C Levels
  Diabetes Care, 2010
• Randomized Clinical Trial of Quick-Release Bromocriptine Among Patients With Type 2 Diabetes on Overall Safety and Cardiovascular Outcomes
  Diabetes Care, 2010
• Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)
  The Lancet, 2009
• From the Triumvirate to the Ominous Octet: A New Paradigm for the Treatment of Type 2 Diabetes Mellitus
  Diabetes, 2009
• 10-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes
  New England Journal of Medicine, 2008
• Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study
  The Lancet, 2008